Schering-Plough Ziracin
Executive Summary
Schering discontinues Phase II and Phase III trials of intravenous antibiotic after results "showed that the balance between efficacy and safety did not justify further development of the product," the company announced May 5. The antibiotic was being developed for treatment of resistant gram positive infections